Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Neuraxis (NRXS) EBT (2022 - 2025)

Neuraxis' EBT history spans 4 years, with the latest figure at -$2.1 million for Q3 2025.

  • For Q3 2025, EBT fell 28.3% year-over-year to -$2.1 million; the TTM value through Sep 2025 reached -$7.0 million, up 7.08%, while the annual FY2024 figure was -$7.2 million, 7.25% down from the prior year.
  • EBT for Q3 2025 was -$2.1 million at Neuraxis, down from -$1.7 million in the prior quarter.
  • Across five years, EBT topped out at -$883005.0 in Q4 2024 and bottomed at -$3.0 million in Q3 2023.
  • The 4-year median for EBT is -$1.7 million (2024), against an average of -$1.7 million.
  • The largest annual shift saw EBT plummeted 131.76% in 2023 before it soared 45.07% in 2024.
  • A 4-year view of EBT shows it stood at -$986225.0 in 2022, then fell by 29.34% to -$1.3 million in 2023, then skyrocketed by 30.78% to -$883005.0 in 2024, then crashed by 141.19% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRXS's EBT are -$2.1 million (Q3 2025), -$1.7 million (Q2 2025), and -$2.3 million (Q1 2025).